Perative

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perative

Property Description
Active ingredient Ketoconazole
Form Cream, Shampoo, Tablets, Gel, Solution, Foam
Pharmacological class Azole Antifungal, Imidazole derivative
General purpose Fungal growth control (Fungistatic)
Origin Synthetic

Perative is a medicine designated as a synthetic, broad-spectrum antifungal agent used to control the proliferation of susceptible fungi and yeasts. It is primarily defined by its sole active ingredient, Ketoconazole, a compound identified as an Imidazole derivative. This classification means the medicine is chemically structured to target the cell integrity of fungal organisms. Ketoconazole is recognized as a key drug in the Azole family for its ability to address fungal proliferation, characterizing the drug’s role as a synthetic agent for managing fungal issues.


What Type of Medicine is Perative and What is it Made Of?

Perative is an antifungal medication whose function is derived entirely from the synthetic compound Ketoconazole, its active substance. Ketoconazole is a single-ingredient product, meaning the pharmacological activity relies solely on this one component. The high-level composition of Perative includes the active substance combined with an inert vehicle, such as an aqueous cream vehicle, specialized shampoo vehicle, or a base for oral tablets, depending on the intended administration route.


What General Forms Does Perative Come In?

Perative is available in multiple dosage forms to address varying needs, distinguishing it through versatility for localized and internal action. The forms include a specialized shampoo, cream, foam, gel, and solution for topical application to the skin or scalp, as well as tablets for systemic (oral) administration. This dual availability provides a wide therapeutic scope, offering solutions for surface conditions versus conditions requiring internal, systemic biological action.


What is the General Purpose of This Antifungal Agent?

The general purpose of Perative is to act as a fungistatic agent, controlling the growth of fungal organisms that can cause health issues in humans. This benefit is achieved because Ketoconazole interferes with the production of ergosterol, a vital component needed to build and maintain the fungal cell membrane structure. By limiting cell wall integrity and halting the ability of susceptible fungi and yeasts to multiply, the medication helps to stabilize conditions caused by their proliferation. Its function is utilized for controlling yeast populations that contribute to chronic skin conditions.

What side effects are possible with Perative?

Possible Side Effects and Safety Information for Perative

This section outlines the safety profile of Perative, as determined and structured by official governmental regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This information is derived exclusively from authoritative government regulatory documents.

Regulatory Safety Summary

The official adverse reaction and safety profile for the product named Perative is not currently available in the publicly accessible documents of major governmental regulatory authorities. Consequently, specific data on adverse reaction frequency, severity, and critical safety notes cannot be provided.

Regulatory agencies follow a strict framework for documenting a medicine’s safety profile, which typically includes the following structured elements:

Safety Classification Element Regulatory Status for Perative
Adverse Reactions by Frequency No specific data found in official regulatory documents.
System-Organ Classes (SOC) Involved No specific data found in official regulatory documents.
Serious Adverse Reactions (Documented) No specific data found in official regulatory documents.
Population-Specific Considerations No specific data found in official regulatory documents.
Safety-Related Restrictions/Limitations No specific data found in official regulatory documents.

Understanding the Official Safety Profile Structure

When a safety profile is finalized by regulatory bodies, it employs a standardized approach to classify and communicate risk. Side effects are organized by the System-Organ Class (SOC), showing which body system is affected (e.g., gastrointestinal or nervous system), and categorized by frequency (e.g., common, uncommon) to indicate how likely they are to occur based on clinical trial data. This structured documentation provides the authoritative basis for understanding the medicine’s risk profile, separating likely events from those that are rare but serious. The lack of specific, published documentation for Perative prevents a complete presentation of this formal regulatory structure.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the official information on Perative (Ketoconazole) overdose, as documented by government regulatory authorities.

Domain Official Regulatory Statement
Documented Manifestations Acute oral overdose symptoms include nausea and vomiting (gastrointestinal distress).
Physiological Systems Affected Potential for adrenal insufficiency (endocrine system) and severe elevated liver enzyme levels (hepatic system).
Exposure-Related Factors Systemic overdose is officially deemed unlikely following the application of topical forms (cream, shampoo) due to minimal absorption.
Urgent Medical Action Required Immediate professional medical attention is required for any suspected overdose or accidental ingestion of oral formulations.

Overdose Management and Monitoring

Classification Official Regulatory Statement
Severity Classification Overdose carries the potential for severe, life-threatening outcomes, including the risk of hepatic complications.
Management Measures Treatment should consist of symptomatic and supportive treatment. Procedures like gastric lavage with activated charcoal may be considered if performed shortly after ingestion.
Antidote and Monitoring Regulatory documents state that no specific antidote is known. Close monitoring in a hospital setting may be required due to the risk of severe complications.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by outlining the potential for serious systemic risks, which mandates the immediate requirement to seek emergency medical attention. Management remains focused on supportive treatment and monitoring, as regulatory agencies confirm the absence of a specific antidote to reverse the effects of a Ketoconazole overdose.

Therapeutic Uses of Perative

What Perative Treats: Main Uses and Benefits

Perative (Ketoconazole) is used across therapeutic domains involving certain distressing symptoms caused by fungal and yeast organisms. The primary role is to provide supportive management in situations involving certain distressing symptoms, which is relevant in contexts marked by increased discomfort or tension and helps ease the overall symptom burden. It is commonly used to treat conditions such as ringworm, jock itch, Athlete's foot, and conditions that produce significant symptomatic burden like seborrheic dermatitis and dandruff.


This antifungal agent may be part of symptomatic management in addressing symptoms related to inflammatory or irritative states caused by fungi, including scaling, flaking, scaly patches, and itching. It supports the management of infections like tinea corporis and tinea pedis, and may assist with maintaining functional stability by reducing visible manifestations. For chronic conditions, it helps improve day-to-day comfort during periods of heightened symptoms. The oral form may be considered for severe systemic fungal infections and recalcitrant dermatophyte infections where previous symptomatic support was insufficient. This provides a supportive role in settings where short-term symptomatic assistance is needed.

“This medication is considered relevant for easing skin and scalp discomfort associated with the persistent presence of certain fungal or yeast populations.”


Quick Fact: Relief for Scaling and Itching

Perative is commonly used across conditions involving episodic or fluctuating manifestations. It assists with managing the symptom clusters that may become disruptive, such as flaking and scaling of the skin, offering symptomatic relief that contributes to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

The eligibility for Perative (Ketoconazole) is strictly defined by regulatory authorities, varying significantly between the oral tablet and topical formulations.

Populations for Whom Use is Contraindicated

The oral tablet is contraindicated in patients with acute or chronic liver disease, as well as in individuals with known hypersensitivity to the drug or its components. Use is also prohibited with a specific list of co-administered medicines, including drugs for heart rhythm, due to the potential for life-threatening events. The oral form is also contraindicated in women who are pregnant or breastfeeding according to European regulatory guidance.

Age- and Condition-Based Eligibility

Population Group Regulatory Status
Pediatric Patients Safety and effectiveness have not been established for most topical forms in children younger than 12 years of age.
Liver Status Patients with pre-existing liver disease must not use the oral tablet.
Reproductive Status Topical forms should be used only if the potential benefit justifies the potential risk during pregnancy or lactation.

Use of the oral tablet is not recommended as first-line treatment for any fungal infection and is limited to specific systemic conditions when alternative therapies are unavailable or not tolerated. Patients with adrenal problems or decreased gastric acidity require special regulatory considerations for use of the oral form.

What should I know about interactions with other medicines?

Perative Interactions with other medicines and products

Perative is a specialized enteral nutritional formula, not a pharmaceutical drug; therefore, it does not have the extensive drug-drug interaction profile found in prescription medication labeling. The primary interaction considerations are centered on the product's nutritional components and required administration route.

Interaction Profile

Interaction Type General Context (from Regulatory Documents)
Drug-Nutrient The product contains Vitamin K, which may interact with anticoagulants such as warfarin. Careful monitoring of anticoagulant activity is essential for patients receiving both this formula and such medications.
Administration For enteral use only (must be administered via the gastrointestinal tract). It is not for parenteral use (injection or intravenous administration).
Incompatibilities Do not make any additions to the feed without consulting a healthcare professional to avoid potential physical or chemical incompatibilities that could compromise the feed or tube integrity, or alter the effectiveness of co-administered medications.
Condition-Specific The product is not for use in patients with galactosemia, a condition that restricts the body's ability to process galactose, a component of the feed.

General Considerations

All use of Perative must be under medical supervision. Given the potential for drug-nutrient interactions, particularly with high-alert medications, appropriate prescribing and monitoring practices by healthcare providers, including pharmacists and dietitians, are required to manage risks.

Mechanism of Action

How Perative Works: Mechanism of Action

Perative’s mechanism of action is derived solely from Ketoconazole, which targets the biological machinery unique to susceptible fungal organisms. The drug’s core activity is the highly specific inhibition of the enzyme cytochrome P450 14alpha-demethylase (CYP51). This enzyme is an essential component of the ergosterol biosynthesis pathway.

The inhibition of CYP51 blocks the necessary conversion of lanosterol into ergosterol, leading to two crucial intracellular consequences: the severe depletion of ergosterol, the primary structural sterol of the fungal cell membrane, and the subsequent accumulation of 14alpha-methylated sterol precursors. This dual effect results in a profound structural failure of the fungal cell membrane, which compromises its integrity, fluidity, and barrier function. The resulting physiological consequence is the direct inhibition of fungal cell multiplication and growth.

Dosage and Administration Information

Instruction Map: How to use Perative (Ketoconazole) — Administration Guidelines

This map summarizes the instructions for using Perative, which contains Ketoconazole.


Administration Scope

Route of administration: The medication is administered via the oral route as a 200 mg tablet or via the topical/cutaneous route using the 2% cream, shampoo, foam, or gel formulation.

Dosing schedule:

  • Adult Oral: The typical starting dose is 200 mg once daily, with the option for the dose to be increased to 400 mg once daily if needed.
  • Pediatric Oral (2 years): The dose is determined by weight, usually 3.3 to 6.6 mg/kg taken orally once a day.

Timing in relation to meals (if applicable): Oral tablets should be taken with food to facilitate absorption of the active substance.

Preparation requirements (if applicable): Topical 2% shampoo requires the user to lather the product and leave it in place for 3 to 5 minutes before rinsing.

Age-group administration rules: Use of the oral tablet form is established for pediatric patients two years of age and older, with dose calculation based on body weight.

Missed-dose rules: If an oral dose is missed, it should be taken as soon as possible. If it is nearly time for the next scheduled dose, the missed dose is skipped, and the regular schedule is resumed. Doses must not be doubled.

Special procedural conditions: All topical forms are restricted to external use only and must not contact the eyes or other mucous membranes.


Instruction Classifications (High-Level)

Administration method type: Oral and Topical.

Frequency pattern: Once daily (oral); Once or twice daily (topical applications); Intermittent/Cyclic (shampoo for specific regimens).

Basis of instructions: Information is based on standard prescribing guidelines.

Use-context constraints: Intake must be concurrent with food (oral form). Topical use requires external application only and adherence to specific procedural contact times.


Resulting Procedural Structure

Step sequence (Topical Shampoo):

  • Apply the 2% shampoo to the damp skin of the affected area and surrounding margin.
  • Lather the product.
  • Leave the lather in place for 3–5 minutes.
  • Rinse off with water.

Connection to the overall use protocol: The usage protocol for this medicine defines two distinct administration methods, oral for systemic action and topical for localized use. These instructions define the necessary dose ranges, frequency patterns, and specific administration techniques (such as taking the tablet with food or adhering to a 5-minute contact time for the shampoo) required to use the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Perative

Perative (Ketoconazole) was studied for various fungal conditions using different formulations, with the research providing context but not individual predictions. The evidence available was studied for defining the types of outcomes related to physical discomfort and how they were measured in specific patient groups.


Evidence for Topical Use in Superficial Skin Infections

The research examining topical Perative for skin conditions such as Ringworm (tinea corporis), Jock Itch (tinea cruris), and Athlete's Foot (tinea pedis) is primarily based on short-term Randomized Controlled Trials (RCTs). These studies explored how physical signs and symptoms evolved over defined time intervals.

Researchers primarily monitored changes in physical findings like scaling, redness (erythema), and skin cracking (fissuring), which are outcomes linked to inflammatory or irritative states. The trials typically included adults who had uncomplicated, culture-confirmed fungal infections; follow-up durations were generally short, covering the treatment period and a brief test-of-cure phase thereafter. There is limited information for long-term outcomes concerning how often the infections return after the study concludes.


Evidence for Topical Use in Seborrheic Dermatitis and Dandruff

Research for the topical forms of Perative in seborrheic dermatitis and dandruff has utilized a combination of double-blind, controlled trials for short-term study phases, alongside longer, observational studies to track patterns over many months. This research examined temporary physiological imbalance associated with these conditions characterized by fluctuating or episodic manifestations.

The studies explored patient-reported outcomes describing perceived discomfort, such as changes in itching and quantifiable signs like flaking and redness. Findings from comparative studies described differing measured outcomes when comparing the medicine to a non-active vehicle or other active agents. Long-term effects are not fully established, meaning data on sustained patterns remains an area of ongoing research.


Evidence for Oral Use in Severe and Recalcitrant Fungal Infections

The research surrounding the oral tablet form of Perative for severe, deep-seated fungal infections and recalcitrant superficial infections is structurally different. The evidence is heavily weighted by historical early clinical trials and case series conducted decades ago, rather than large-scale, contemporary RCTs.

The current application of the oral medicine is subject to regulatory restrictions in many countries, which limits its application to when alternative treatment options cannot be used or have not provided adequate results. This reflects that the certainty remains low when comparing the evidence for this older systemic treatment against modern alternatives.


Research Gaps and Areas of Scientific Uncertainty

The research available highlights what is known—and what is still uncertain—about this medicine. For the oral systemic use, the evidence relies heavily on historical data, and the comparative evidence is lacking when assessed against newer antifungal agents. Evidence quality varies across studies depending on the specific formulation, and subgroup findings are uncertain when looking at patients with significant comorbidities.

Key Studies & References Ketoconazole - StatPearls (Overview of indications, dosage forms, and historical context)

Frequently Asked Questions (FAQ)

Common questions about Perative (FAQ)

Q: Is Perative a treatment or a maintenance drug?

Official documents suggest that the oral tablet is primarily intended for treatment. It is specifically indicated for addressing certain systemic fungal infections, particularly when other available options have not been successful or cannot be tolerated. This focuses its role on actively treating a severe condition rather than long-term maintenance.


Q: Does Perative treat the cause or just the symptoms?

Official information describes the medication's mechanism of action as addressing the underlying biological process of the fungal infection. This involves interfering with a vital enzyme that fungal cells need to build and maintain their cell membranes, which acts to control the growth and multiplication of the fungus.


Q: How does Perative work in simple terms?

In simple terms, Perative works by acting directly on the fungal organisms. Its active ingredient prevents the fungal cells from producing ergosterol, which is a vital material they require for their cell structure. By affecting this process, the medication acts to control the growth and spread of susceptible fungi.


Q: Are the side effects of Perative permanent or temporary?

The duration of many common side effects is not specified in regulatory documents. However, for the serious risk of liver injury (hepatotoxicity), official information indicates that it is often reversible once the medicine is discontinued. It is noted that this severe adverse effect is not always reversible.


Q: Does Perative cause long-term kidney or liver problems?

According to official regulatory documents, the oral tablet carries a Black Box Warning because of the potential for severe, sometimes fatal, liver injury (hepatotoxicity). This serious risk has been reported to occur after both short and extended periods of use. Information on long-term kidney problems as a primary safety warning is not provided.


Q: Are there any foods or drinks I should avoid while taking Perative?

Official information advises against the consumption of grapefruit and grapefruit juice while taking the oral tablet. This caution is advised because consuming grapefruit can raise the levels of the medicine in the blood, which may increase the risk of experiencing adverse effects.


Q: Does Perative require any special tests before starting treatment?

Official guidance indicates that certain monitoring tests are generally recommended or necessary before and during treatment with the oral tablet. These commonly include blood tests to check liver function and an ECG (electrocardiogram) to check the heart's rhythm. These precautions are taken to help monitor for unwanted effects.


Q: Is Perative meant to be taken for a short period or for the long-term?

Official regulatory texts indicate that the oral tablet is generally not intended for long-term, continuous use due to the risk of serious side effects. For continuing therapy, some international authorities have advised restricting the maximum treatment duration to about four weeks.


Q: Why is Perative prescribed when other treatments are available?

Official information states that the oral tablet should only be used in limited circumstances. Specifically, the FDA label restricts its use to situations where the potential benefits of treating a serious infection are considered to outweigh the risks, and when other effective antifungal options are unavailable or cannot be tolerated.


Q: Is Perative considered a high-risk medication?

Yes, the oral tablet is considered a medication with serious potential risks. It carries a Black Box Warning from the FDA—the agency’s most serious warning—because of the potential for fatal liver injury and serious drug interactions. This designation reflects the serious nature of the medication.


Q: Can Perative cause weight gain or weight loss?

Official documents list loss of appetite (anorexia) as a reported side effect of the oral tablet. This effect, along with subsequent weight loss, has been reported and can sometimes be linked to potential hormone issues or liver problems. Weight gain is not commonly listed in the safety summary.


Q: What happens if I stop taking Perative suddenly?

Regulatory sources caution against suddenly stopping the oral tablet. If there is any concern or desire to discontinue use, the official guidance is to always discuss it with a healthcare provider beforehand.


Q: Is nausea a common side effect when first starting Perative?

Yes, according to official information, nausea is listed as one of the most common side effects reported with the use of the oral tablet.


Q: Can Perative affect my sleep patterns?

Official safety summaries list difficulty falling asleep or staying asleep (insomnia) as a potential side effect of the medicine.


Q: How long do the common side effects usually last?

Generally, common side effects are described as mild in nature. In many cases, these temporary effects may resolve or go away on their own within a few days or a couple of weeks as the body adjusts to the medication.


Q: Is Perative known to cause fatigue or tiredness?

Yes, regulatory documents list weakness and unusual tiredness as reported side effects. These can be direct effects of the medicine or, in some cases, symptoms that relate to potential adrenal insufficiency or liver problems.


Q: Does Perative affect mental clarity or focus?

Official safety summaries report side effects such as dizziness and headache, which could potentially affect concentration or focus. Additionally, mental or mood changes, including depression, have been reported in some patients using the oral tablet.


Q: Does Perative interact with common vitamins like Vitamin D or B12?

The official regulatory label lists numerous serious drug interactions. While specific interactions with common vitamins are not typically detailed, official information recommends disclosing all vitamins, minerals, and herbal products to a healthcare provider.


Q: What does official guidance say about Perative and alcohol consumption?

Official regulatory guidance cautions against the consumption of alcoholic beverages while using the oral tablet. This is due to the potential for the combination to significantly increase the risk of serious or fatal liver damage.


Q: Does Perative interact with any common over-the-counter cold medicines?

The medication is known to be a potent enzyme inhibitor, leading to many specific drug interactions listed in the official documents. Official guidance indicates that any over-the-counter (OTC) medicines, including cold medicines, should be discussed with a healthcare provider.


Q: Does smoking affect how Perative works?

The official label for the topical foam formulation includes a warning that patients should not be near fire, flame, or smoking during and immediately after application. This is because the foam product is flammable.


Q: Is Perative generally considered safe for older adults?

Official documents note that for the oral tablet, no specific information is available on how the medicine's effects in geriatric patients compare to younger adults. For the topical formulations, regulatory documents note that greater sensitivity of some older individuals cannot be ruled out.


Q: How quickly should I expect to see an effect from Perative?

Regulatory sources indicate that after taking a single oral dose with a meal, the drug reaches its highest concentration in the blood (known as peak plasma levels) within approximately 1 to 2 hours.


Q: What is the typical duration of Perative treatment described in clinical trials?

While the duration of treatment varies depending on the specific infection being addressed, some international regulatory guidance advises restricting oral treatment to a maximum of four weeks. This limitation is typically based on safety concerns related to systemic exposure.


Q: What is the half-life of Perative?

Regulatory documents describe the elimination of the medicine from the blood as biphasic, meaning it occurs in two distinct phases. The half-life is approximately 2 hours during the first 10 hours and increases to about 8 hours after that time.


Q: If Perative doesn't seem to be working, what is the usual next step described in research?

Official safety information indicates that if the condition does not improve or if symptoms become worse, consultation with a healthcare provider is warranted.


Q: Why is Perative sometimes preferred over non-prescription options?

The oral tablet is typically reserved for serious systemic infections and is not preferred for routine use. The FDA label restricts its use to situations where alternative therapies are not available or are not tolerated, suggesting it is primarily chosen for conditions severe enough to require a regulated, high-risk systemic medication.


Q: Is it normal to feel a change in appetite after starting Perative?

Yes, official safety information lists loss of appetite (anorexia) as a reported side effect of the oral tablet. It is noted that a loss of appetite can also be a symptom of a more serious adverse reaction, such as a potential liver problem.


Q: Are there any known issues with Perative and driving or operating machinery?

Yes, the safety summary reports side effects such as dizziness, feeling lightheaded, or fainting (syncope), which is linked to potential heart rhythm changes. These reported effects are associated with the ability to safely operate machinery or drive.

How should Perative be stored and disposed of?

How to Store and Dispose of Perative (Ketoconazole)

Official regulatory documents define strict storage and disposal requirements for Perative.

Storage Requirements

Perative must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept from freezing, especially liquid and cream forms, and stored away from excessive heat and moisture (such as in the bathroom).

Mandatory conditions require keeping the medicine in its original container and ensuring it is tightly closed to protect it from light and maintain stability. The medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Perative must not be disposed of via household wastewater or sewage. The preferred method is to use a drug take-back program or consult a pharmacist for specific disposal guidance to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perative found in:

A-Z Index: